secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001193125-23-091011
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos amends license with Precigen; returns CAR/IL-12 rights, eliminates all payment obligations
--------------------------------------------------------------------------------

- Alaunos returns exclusive rights to CAR (CD19 & BCMA) and IL-12 products to Precigen; retains TCR and Sleeping Beauty licenses.
- All Alaunos development and commercialization obligations under the license are eliminated.
- Alaunos no longer owes milestone payments (up to $52.5M per program) or royalties; Precigen's royalty obligations also removed.
- Annual license payment reduced from $100,000 to $75,000.
- License term now tied to expiration of last valid patent claim instead of later of patent life or 12 years post-first commercial sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/0001193125-23-091011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523091011/d429387d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-091011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer